BNR - Company ID 0001792267
Burning Rock Biotech Ltd trades as BNR. In its fiscal 2025 annual report the company posted revenue of $77.16M, up 9.2% from the prior year and net income of -$7.92M. This page tracks Burning Rock Biotech Ltd through 166 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Burning Rock Biotech Ltd's revenue grew from $65.89M to $77.16M, a compound annual growth rate of 3.2%. Net profit margin expanded from -94.7% to -10.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| 20-F | - | 2026-04-28 |
| Insider trade | 4 | 2026-04-02 |
| New insider ownership | 3 | 2026-03-18 |
| New insider ownership | 3 | 2026-03-17 |
| New insider ownership | 3 | 2026-03-17 |
| New insider ownership | 3 | 2026-03-17 |
The largest companies sharing Burning Rock Biotech Ltd's SEC industry classification (services-medical laboratories).
Burning Rock Biotech Ltd reported revenue of $77.16M for fiscal year 2025, an increase of 9.2% year over year.
In its latest fiscal year Burning Rock Biotech Ltd reported a net loss of $7.92M.